The Effect of Ocrelizumab on the Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in Patients With Multiple Sclerosis Previously Treated With Disease Modifying Therapy - A Prospective Exploratory Observational Study
Latest Information Update: 03 May 2023
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 28 Apr 2023 Planned End Date changed from 1 May 2024 to 1 Nov 2023.
- 28 Apr 2023 Planned primary completion date changed from 1 May 2023 to 1 Nov 2023.
- 28 Apr 2023 Status has been changed from to active, no longer recruiting.